- Home
- YSG vs PSNL Comparison
YSG vs PSNL Comparison
Compare YSG & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YSG
- PSNL
- Stock Information
- Founded
- YSG 2016
- PSNL 2011
- Country
- YSG China
- PSNL United States
- Employees
- YSG N/A
- PSNL N/A
- Industry
- YSG Package Goods/Cosmetics
- PSNL Medical Specialities
- Sector
- YSG Consumer Discretionary
- PSNL Health Care
- Exchange
- YSG Nasdaq
- PSNL Nasdaq
- Market Cap
- YSG 529.3M
- PSNL 426.6M
- IPO Year
- YSG 2020
- PSNL 2019
- Fundamental
- Price
- YSG $9.48
- PSNL $6.42
- Analyst Decision
- YSG
- PSNL Strong Buy
- Analyst Count
- YSG 0
- PSNL 5
- Target Price
- YSG N/A
- PSNL $8.00
- AVG Volume (30 Days)
- YSG 599.8K
- PSNL 922.2K
- Earning Date
- YSG 08-19-2025
- PSNL 08-06-2025
- Dividend Yield
- YSG N/A
- PSNL N/A
- EPS Growth
- YSG N/A
- PSNL N/A
- EPS
- YSG N/A
- PSNL N/A
- Revenue
- YSG $475,930,821.00
- PSNL $85,694,000.00
- Revenue This Year
- YSG $17.93
- PSNL $0.45
- Revenue Next Year
- YSG $12.79
- PSNL $25.75
- P/E Ratio
- YSG N/A
- PSNL N/A
- Revenue Growth
- YSG 0.90
- PSNL 15.57
- 52 Week Low
- YSG $2.60
- PSNL $1.14
- 52 Week High
- YSG $9.81
- PSNL $7.20
- Technical
- Relative Strength Index (RSI)
- YSG 80.20
- PSNL 72.69
- Support Level
- YSG $8.55
- PSNL $6.06
- Resistance Level
- YSG $9.81
- PSNL $6.72
- Average True Range (ATR)
- YSG 0.81
- PSNL 0.44
- MACD
- YSG 0.22
- PSNL 0.10
- Stochastic Oscillator
- YSG 92.55
- PSNL 85.65
About YSG Yatsen Holding Limited
Yatsen Holding Ltd is engaged in the retail business of beauty products, skincare items, and other cosmetic products. The group's principal operations are currently organized into three segments on a product category basis, namely Color Cosmetics Brands, Skincare Brands, and others. The company's majority of revenue is generated from sales of Color Cosmetics Brands.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.